Collegium Pharmaceutical Inc (COLL)

Track

Over the past 90 days, Collegium Pharmaceutical Inc. saw 11 insider transactions, all of which were sales totaling approximately $2.19 million. Four insiders, including directors and former directors, offloaded shares. These transactions occurred following the company's May 2026 earnings report, which showed an EPS beat of 15.79%. No insider buying was recorded during this period.

Active selling signal · Exceptional

Top insider sells (90d)

Top cluster sells (90d)

Featured in screeners

Active selling signal · Exceptional

Top insider sells

Top cluster sells

Ticker: COLL Exchange: NSM

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings

Insider activity signal detected

10 activity signals detected for Collegium Pharmaceutical Inc

Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Collegium Pharmaceutical Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →

Top insiders

Company data & Insiders

Subscribe to get access to the company description and key fundamental data (market cap, shares outstanding, dividend yield, % of shares held by insiders and more)

Download results Settings

Trades

Fallon John A.

Former Director

1 sale — total 100,000 USD

Proposed sale 17 Jul 2026

Value US$3,547,799.44 | Price 374.12 | Shares 5,642

Fallon John A.

Former Director

1 sale — total 100,000 USD

Proposed sale 15 Jul 2026

Value US$511,564.38 | Price 438.29 | Shares 89,746

Freund John Gordon

2 sales — total 1,703 USD

Sale 18 May 2026

Value US$681.00 | Price 34.05 | Shares 20

Proposed sale 18 May 2026

Value US$1,021.50 | Price 34.05 | Shares 30

Freund John Gordon

3 sales — total 427,640 USD

Sale 15 May 2026

Value US$142,546.58 | Price 34.54 | Shares 4,127

Sale 15 May 2026

Value US$142,546.58 | Price 34.54 | Shares 4,127

Proposed sale 15 May 2026

Value US$142,546.99 | Price 34.54 | Shares 4,127

Lurker Nancy

2 sales — total 323,722 USD

Sale 13 May 2026

Value US$161,860.95 | Price 35.97 | Shares 4,500

Proposed sale 13 May 2026

Value US$161,861.16 | Price 35.97 | Shares 4,500

BOHLIN GAREN G

2 sales — total 646,982 USD

Sale 11 May 2026

Value US$323,491.23 | Price 37.18 | Shares 8,700

Proposed sale 11 May 2026

Value US$323,491.00 | Price 37.18 | Shares 8,700

Dieter David

EVP & General Counsel

2 sales — total 976,198 USD

Planned sale 18 Mar 2026

Value US$488,099.22 | Price 34.92 | Shares 13,976

Proposed sale 18 Mar 2026

Value US$488,098.93 | Price 34.92 | Shares 13,976

Dieter David

EVP & General Counsel

2 sales — total 456,219 USD

Planned sale 9 Mar 2026

Value US$228,109.60 | Price 36.65 | Shares 6,224

Proposed sale 9 Mar 2026

Value US$228,109.60 | Price 36.65 | Shares 6,224

Dreyer Scott

EVP & Chief Commercial Officer

3 sales — total 4,038,876 USD

Planned sale 3 Mar 2026

Value US$145,879.50 | Price 40.99 | Shares 3,559

Planned sale 3 Mar 2026

Value US$1,873,557.22 | Price 40.36 | Shares 46,417

Proposed sale 3 Mar 2026

Value US$2,019,439.23 | Price 40.41 | Shares 49,976

Dreyer Scott

EVP & Chief Commercial Officer

3 sales — total 1,695,710 USD

Planned sale 8 Dec 2025

Value US$315,084.51 | Price 48.66 | Shares 6,475

Planned sale 8 Dec 2025

Value US$532,770.69 | Price 47.89 | Shares 11,125

Proposed sale 8 Dec 2025

Value US$847,855.26 | Price 48.17 | Shares 17,600

RITA BALICE-GORDON

DIRECTOR

1 sale — total 171,673 USD

Proposed sale 5 Dec 2025

Value US$171,672.76 | Price 47.03 | Shares 3,650

Balice-Gordon Rita J.

1 sale — total 171,673 USD

Sale 5 Dec 2025

Value US$171,673.37 | Price 47.03 | Shares 3,650

Fallon John A.

2 sales — total 3,291,072 USD

Sale 12 Nov 2025

Value US$1,645,535.60 | Price 47.21 | Shares 34,853

Proposed sale 12 Nov 2025

Value US$1,645,536.24 | Price 47.21 | Shares 34,853

Tupper Colleen

EVP & Chief Financial Officer

3 sales — total 2,431,507 USD

Planned sale 6 Nov 2025

Value US$200,516.86 | Price 41.28 | Shares 4,858

Planned sale 6 Nov 2025

Value US$1,015,236.47 | Price 40.38 | Shares 25,142

Proposed sale 6 Nov 2025

Value US$1,215,753.81 | Price 40.53 | Shares 30,000

Smith Thomas B

EVP and Chief Medical Officer

2 sales — total 1,343,153 USD

Sale 29 Aug 2025

Value US$671,576.42 | Price 38.42 | Shares 17,478

Proposed sale 29 Aug 2025

Value US$671,576.38 | Price 38.42 | Shares 17,478

Dreyer Scott

EVP & Chief Commercial Officer

2 sales — total 1,252,342 USD

Planned sale 18 Aug 2025

Value US$626,171.25 | Price 38.21 | Shares 16,389

Proposed sale 18 Aug 2025

Value US$626,170.29 | Price 38.21 | Shares 16,389

SANTINI GINO

2 sales — total 402,037 USD

Sale 15 Aug 2025

Value US$201,018.44 | Price 37.19 | Shares 5,405

Proposed sale 15 Aug 2025

Value US$201,018.82 | Price 37.19 | Shares 5,405

Dreyer Scott

EVP & Chief Commercial Officer

2 sales — total 369,762 USD

Planned sale 13 Aug 2025

Value US$184,880.84 | Price 38.03 | Shares 4,861

Proposed sale 13 Aug 2025

Value US$184,880.87 | Price 38.03 | Shares 4,861

Rubric Capital Management LP

1 sale — total 946,250 USD

Sale 13 Aug 2025

Value US$946,250.00 | Price 37.85 | Shares 25,000

Freund John Gordon

1 sale — total 400,641 USD

Sale 8 Aug 2025

Value US$400,640.55 | Price 34.36 | Shares 11,659

Heffernan Michael Thomas

Former Director

1 sale — total 332,269 USD

Proposed sale 9 Jul 2025

Value US$332,268.77 | Price 32.17 | Shares 10,328

Heffernan Michael Thomas

Former Director

1 sale — total 24,792 USD

Proposed sale 8 Jul 2025

Value US$24,792.05 | Price 31.38 | Shares 790

Heffernan Michael Thomas

Former Director

1 sale — total 444,062 USD

Proposed sale 7 Jul 2025

Value US$444,062.16 | Price 31.25 | Shares 14,210

Heffernan Michael Thomas

Former Director

1 sale — total 757,380 USD

Proposed sale 2 Jul 2025

Value US$757,379.85 | Price 30.30 | Shares 25,000

Melincoff Gwen A

Former Director

1 sale — total 1,425,971 USD

Proposed sale 2 Jul 2025

Value US$1,425,970.65 | Price 30.29 | Shares 47,082

Freund John Gordon

2 sales — total 404,297 USD

Sale 9 Jun 2025

Value US$202,149.02 | Price 30.62 | Shares 6,601

Proposed sale 9 Jun 2025

Value US$202,148.36 | Price 30.62 | Shares 6,601

Tupper Colleen

EVP & Chief Financial Officer

2 sales — total 384,137 USD

Planned sale 21 Mar 2025

Value US$192,068.68 | Price 30.03 | Shares 6,396

Proposed sale 21 Mar 2025

Value US$192,068.63 | Price 30.03 | Shares 6,396

Dreyer Scott

EVP & Chief Commercial Officer

2 sales — total 1,133,967 USD

Planned sale 21 Mar 2025

Value US$566,983.21 | Price 30.03 | Shares 18,881

Proposed sale 21 Mar 2025

Value US$566,983.70 | Price 30.03 | Shares 18,881

Tupper Colleen

EVP & Chief Financial Officer

2 sales — total 72,363 USD

Planned sale 20 Mar 2025

Value US$36,181.33 | Price 30.00 | Shares 1,206

Proposed sale 20 Mar 2025

Value US$36,181.38 | Price 30.00 | Shares 1,206

Dreyer Scott

EVP & Chief Commercial Officer

2 sales — total 115,622 USD

Planned sale 20 Mar 2025

Value US$57,810.96 | Price 30.00 | Shares 1,927

Proposed sale 20 Mar 2025

Value US$57,810.99 | Price 30.00 | Shares 1,927

Kuhlmann Shirley R.

Former Officer

1 sale — total 1,200,632 USD

Proposed sale 20 Mar 2025

Value US$1,200,631.78 | Price 29.65 | Shares 40,494

Dreyer Scott

EVP & Chief Commercial Officer

2 sales — total 135,322 USD

Planned sale 14 Mar 2025

Value US$67,661.05 | Price 30.00 | Shares 2,255

Proposed sale 14 Mar 2025

Value US$67,661.00 | Price 30.00 | Shares 2,255

Tupper Colleen

EVP & Chief Financial Officer

2 sales — total 58,627 USD

Planned sale 14 Mar 2025

Value US$29,313.32 | Price 30.00 | Shares 977

Proposed sale 14 Mar 2025

Value US$29,313.32 | Price 30.00 | Shares 977

Tupper Colleen

EVP & Chief Financial Officer

2 sales — total 626,825 USD

Planned sale 11 Mar 2025

Value US$313,412.67 | Price 30.01 | Shares 10,445

Proposed sale 11 Mar 2025

Value US$313,412.77 | Price 30.01 | Shares 10,445

Dreyer Scott

Officer

1 sale — total 461,672 USD

Proposed sale 11 Mar 2025

Value US$461,671.90 | Price 30.00 | Shares 15,387

Tupper Colleen

EVP & Chief Financial Officer

2 sales — total 90,242 USD

Planned sale 7 Mar 2025

Value US$45,121.05 | Price 30.00 | Shares 1,504

Proposed sale 7 Mar 2025

Value US$45,121.00 | Price 30.00 | Shares 1,504

Dreyer Scott

EVP & Chief Commercial Officer

2 sales — total 140,892 USD

Planned sale 7 Mar 2025

Value US$70,445.87 | Price 30.00 | Shares 2,348

Proposed sale 7 Mar 2025

Value US$70,445.81 | Price 30.00 | Shares 2,348

Dreyer Scott

EVP & Chief Commercial Officer

3 sales — total 659,379 USD

Planned sale 6 Mar 2025

Value US$461,671.55 | Price 30.00 | Shares 15,387

Planned sale 6 Mar 2025

Value US$98,853.62 | Price 30.00 | Shares 3,295

Proposed sale 6 Mar 2025

Value US$98,853.50 | Price 30.00 | Shares 3,295

Tupper Colleen

EVP & Chief Financial Officer

2 sales — total 116,940 USD

Planned sale 6 Mar 2025

Value US$58,470.00 | Price 30.00 | Shares 1,949

Proposed sale 6 Mar 2025

Value US$58,470.00 | Price 30.00 | Shares 1,949

Kuhlmann Shirley R.

Officer

2 sales — total 1,485,891 USD

Proposed sale 6 Mar 2025

Value US$742,945.50 | Price 28.50 | Shares 26,067

Sale 6 Mar 2025

Value US$742,945.99 | Price 28.50 | Shares 26,067

Kuhlmann Shirley R.

EVP and General Counsel

2 sales — total 1,121,056 USD

Sale 5 Mar 2025

Value US$560,528.00 | Price 28.03 | Shares 20,000

Proposed sale 5 Mar 2025

Value US$560,528.07 | Price 28.03 | Shares 20,000

Kuhlmann Shirley R.

EVP and General Counsel

1 sale — total 1,123,160 USD

Sale 4 Mar 2025

Value US$1,123,160.00 | Price 28.08 | Shares 40,000

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	B/S Transaction type	Insider and/or position	Nb. shares Price Value	Number of shares	Price	Value
2026-07-17	2026-07-17	PrS Proposed sale	2.2 Fallon John A. Former Director Non-Executive Director	5,642 374.12 US$3,547,799	5,642	374.12	US$3,547,799
2026-07-15	2026-07-15	PrS Proposed sale	2.2 Fallon John A. Former Director Non-Executive Director	89,746 438.29 US$511,564	89,746	438.29	US$511,564
2026-05-20	2026-05-18	S Sale	2.2 Freund John Gordon Non-Executive Director	73,430 -27.9% 178.52 US$1,303,739	73,430 -27.9%	178.52	US$1,303,739
2026-05-18	2026-05-18	PrS Proposed sale	2.2 Freund John Gordon Director Non-Executive Director	30 34.05 US$1,022	30	34.05	US$1,022
2026-05-18	2026-05-15	S Sale	2.2 Freund John Gordon Non-Executive Director	4,127 -4.7% 34.54 US$142,547	4,127 -4.7%	34.54	US$142,547
2026-05-18	2026-05-15	S Sale	2.2 Freund John Gordon Non-Executive Director	4,127 -4.7% 34.54 US$142,547	4,127 -4.7%	34.54	US$142,547
2026-05-15	2026-05-15	PrS Proposed sale	2.2 Freund John Gordon Director Non-Executive Director	4,127 34.54 US$142,547	4,127	34.54	US$142,547
2026-05-15	2026-05-13	S Sale	3.4 Lurker Nancy Non-Executive Director	4,500 -20.0% 35.97 US$161,861	4,500 -20.0%	35.97	US$161,861
2026-05-13	2026-05-13	PrS Proposed sale	3.4 Lurker Nancy Director Non-Executive Director	4,500 35.97 US$161,861	4,500	35.97	US$161,861
2026-05-13	2026-05-11	S Sale	2.0 BOHLIN GAREN G Non-Executive Director	8,700 -12.3% 37.18 US$323,491	8,700 -12.3%	37.18	US$323,491
2026-05-11	2026-05-11	PrS Proposed sale	2.0 BOHLIN GAREN G Director Non-Executive Director	8,700 37.18 US$323,491	8,700	37.18	US$323,491
2026-03-20	2026-03-18	PlS Planned sale	Dieter David EVP & General Counsel Officer	13,976 -15.4% 34.92 US$488,099	13,976 -15.4%	34.92	US$488,099
2026-03-18	2026-03-18	PrS Proposed sale	Dieter David Officer Officer	13,976 34.92 US$488,099	13,976	34.92	US$488,099
2026-03-11	2026-03-09	PlS Planned sale	Dieter David EVP & General Counsel Officer	6,224 -6.4% 36.65 US$228,110	6,224 -6.4%	36.65	US$228,110
2026-03-09	2026-03-09	PrS Proposed sale	Dieter David Officer Officer	6,224 36.65 US$228,110	6,224	36.65	US$228,110
2026-03-05	2026-03-03	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	3,559 -4.7% 40.99 US$145,879	3,559 -4.7%	40.99	US$145,879
2026-03-05	2026-03-03	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	46,417 -38.1% 40.36 US$1,873,557	46,417 -38.1%	40.36	US$1,873,557
2026-03-03	2026-03-03	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	49,976 40.41 US$2,019,439	49,976	40.41	US$2,019,439
2025-12-10	2025-12-08	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	6,475 -5.9% 48.66 US$315,085	6,475 -5.9%	48.66	US$315,085
2025-12-10	2025-12-08	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	11,125 -9.2% 47.89 US$532,771	11,125 -9.2%	47.89	US$532,771
2025-12-08	2025-12-08	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	17,600 48.17 US$847,855	17,600	48.17	US$847,855
2025-12-17	2025-12-05	PrS Proposed sale	3.1 RITA BALICE-GORDON DIRECTOR Non-Executive Director	3,650 47.03 US$171,673	3,650	47.03	US$171,673
2025-12-09	2025-12-05	S Sale	3.1 Balice-Gordon Rita J. Non-Executive Director	3,650 -6.5% 47.03 US$171,673	3,650 -6.5%	47.03	US$171,673
2025-11-14	2025-11-12	S Sale	2.2 Fallon John A. Non-Executive Director	34,853 -35.0% 47.21 US$1,645,536	34,853 -35.0%	47.21	US$1,645,536
2025-11-12	2025-11-12	PrS Proposed sale	2.2 Fallon John A. Director Non-Executive Director	34,853 47.21 US$1,645,536	34,853	47.21	US$1,645,536
2025-11-07	2025-11-06	PlS Planned sale	Tupper Colleen EVP & Chief Financial Officer Officer	4,858 -3.7% 41.28 US$200,517	4,858 -3.7%	41.28	US$200,517
2025-11-07	2025-11-06	PlS Planned sale	Tupper Colleen EVP & Chief Financial Officer Officer	25,142 -16.0% 40.38 US$1,015,236	25,142 -16.0%	40.38	US$1,015,236
2025-11-06	2025-11-06	PrS Proposed sale	Tupper Colleen Officer Officer	30,000 40.53 US$1,215,754	30,000	40.53	US$1,215,754
2025-09-03	2025-08-29	S Sale	2.5 Smith Thomas B EVP and Chief Medical Officer Officer	17,478 -19.9% 38.42 US$671,576	17,478 -19.9%	38.42	US$671,576
2025-08-29	2025-08-29	PrS Proposed sale	2.5 Smith Thomas B Officer Officer	17,478 38.42 US$671,576	17,478	38.42	US$671,576
2025-08-20	2025-08-18	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	16,389 -13.7% 38.21 US$626,171	16,389 -13.7%	38.21	US$626,171
2025-08-18	2025-08-18	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	16,389 38.21 US$626,170	16,389	38.21	US$626,170
2025-08-19	2025-08-15	S Sale	2.1 SANTINI GINO Non-Executive Director	5,405 -5.4% 37.19 US$201,018	5,405 -5.4%	37.19	US$201,018
2025-08-15	2025-08-15	PrS Proposed sale	2.1 SANTINI GINO Director Non-Executive Director	5,405 37.19 US$201,019	5,405	37.19	US$201,019
2025-08-15	2025-08-13	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	4,861 -4.5% 38.03 US$184,881	4,861 -4.5%	38.03	US$184,881
2025-08-15	2025-08-13	S Sale	3.6 Rubric Capital Management LP Large shareholder	25,000 -0.8% 37.85 US$946,250	25,000 -0.8%	37.85	US$946,250
2025-08-13	2025-08-13	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	4,861 38.03 US$184,881	4,861	38.03	US$184,881
2025-08-12	2025-08-08	S Sale	2.2 Freund John Gordon Non-Executive Director	11,659 -33.5% 34.36 US$400,641	11,659 -33.5%	34.36	US$400,641
2025-07-09	2025-07-09	PrS Proposed sale	Heffernan Michael Thomas Former Director Non-Executive Director	10,328 32.17 US$332,269	10,328	32.17	US$332,269
2025-07-08	2025-07-08	PrS Proposed sale	Heffernan Michael Thomas Former Director Non-Executive Director	790 31.38 US$24,792	790	31.38	US$24,792
2025-07-07	2025-07-07	PrS Proposed sale	Heffernan Michael Thomas Former Director Non-Executive Director	14,210 31.25 US$444,062	14,210	31.25	US$444,062
2025-07-02	2025-07-02	PrS Proposed sale	Heffernan Michael Thomas Former Director Non-Executive Director	25,000 30.30 US$757,380	25,000	30.30	US$757,380
2025-07-02	2025-07-02	PrS Proposed sale	3.1 Melincoff Gwen A Former Director Non-Executive Director	47,082 30.29 US$1,425,971	47,082	30.29	US$1,425,971
2025-06-11	2025-06-09	S Sale	2.2 Freund John Gordon Non-Executive Director	6,601 -8.5% 30.62 US$202,149	6,601 -8.5%	30.62	US$202,149
2025-06-09	2025-06-09	PrS Proposed sale	2.2 Freund John Gordon Director Non-Executive Director	6,601 30.62 US$202,148	6,601	30.62	US$202,148
2025-03-24	2025-03-21	PlS Planned sale	Tupper Colleen EVP & Chief Financial Officer Officer	6,396 -3.9% 30.03 US$192,069	6,396 -3.9%	30.03	US$192,069
2025-03-24	2025-03-21	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	18,881 -15.4% 30.03 US$566,983	18,881 -15.4%	30.03	US$566,983
2025-03-21	2025-03-21	PrS Proposed sale	Tupper Colleen Officer Officer	6,396 30.03 US$192,069	6,396	30.03	US$192,069
2025-03-21	2025-03-21	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	18,881 30.03 US$566,984	18,881	30.03	US$566,984
2025-03-24	2025-03-20	PlS Planned sale	Tupper Colleen EVP & Chief Financial Officer Officer	1,206 -0.7% 30.00 US$36,181	1,206 -0.7%	30.00	US$36,181
2025-03-24	2025-03-20	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	1,927 -1.5% 30.00 US$57,811	1,927 -1.5%	30.00	US$57,811
2025-03-20	2025-03-20	PrS Proposed sale	Tupper Colleen Officer Officer	1,206 30.00 US$36,181	1,206	30.00	US$36,181
2025-03-20	2025-03-20	PrS Proposed sale	2.3 Kuhlmann Shirley R. Former Officer Officer	40,494 29.65 US$1,200,632	40,494	29.65	US$1,200,632
2025-03-20	2025-03-20	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	1,927 30.00 US$57,811	1,927	30.00	US$57,811
2025-03-18	2025-03-14	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	2,255 -1.8% 30.00 US$67,661	2,255 -1.8%	30.00	US$67,661
2025-03-18	2025-03-14	PlS Planned sale	Tupper Colleen EVP & Chief Financial Officer Officer	977 -0.6% 30.00 US$29,313	977 -0.6%	30.00	US$29,313
2025-03-14	2025-03-14	PrS Proposed sale	Tupper Colleen Officer Officer	977 30.00 US$29,313	977	30.00	US$29,313
2025-03-14	2025-03-14	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	2,255 30.00 US$67,661	2,255	30.00	US$67,661
2025-03-13	2025-03-11	PlS Planned sale	Tupper Colleen EVP & Chief Financial Officer Officer	10,445 -5.9% 30.01 US$313,413	10,445 -5.9%	30.01	US$313,413
2025-03-11	2025-03-11	PrS Proposed sale	Tupper Colleen Officer Officer	10,445 30.01 US$313,413	10,445	30.01	US$313,413
2025-03-11	2025-03-11	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	15,387 30.00 US$461,672	15,387	30.00	US$461,672
2025-03-10	2025-03-07	PlS Planned sale	Tupper Colleen EVP & Chief Financial Officer Officer	1,504 -0.8% 30.00 US$45,121	1,504 -0.8%	30.00	US$45,121
2025-03-10	2025-03-07	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	2,348 -1.6% 30.00 US$70,446	2,348 -1.6%	30.00	US$70,446
2025-03-07	2025-03-07	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	2,348 30.00 US$70,446	2,348	30.00	US$70,446
2025-03-07	2025-03-07	PrS Proposed sale	Tupper Colleen Officer Officer	1,504 30.00 US$45,121	1,504	30.00	US$45,121
2025-03-13	2025-03-06	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	15,387 -10.8% 30.00 US$461,672	15,387 -10.8%	30.00	US$461,672
2025-03-10	2025-03-06	PlS Planned sale	Tupper Colleen EVP & Chief Financial Officer Officer	1,949 -1.1% 30.00 US$58,470	1,949 -1.1%	30.00	US$58,470
2025-03-10	2025-03-06	PlS Planned sale	1.9 Dreyer Scott EVP & Chief Commercial Officer Officer	3,295 -2.2% 30.00 US$98,854	3,295 -2.2%	30.00	US$98,854
2025-03-06	2025-03-06	PrS Proposed sale	Tupper Colleen Officer Officer	1,949 30.00 US$58,470	1,949	30.00	US$58,470
2025-03-06	2025-03-06	PrS Proposed sale	1.9 Dreyer Scott Officer Officer	3,295 30.00 US$98,854	3,295	30.00	US$98,854
2025-03-06	2025-03-06	PrS Proposed sale	2.3 Kuhlmann Shirley R. Officer Officer	26,067 28.50 US$742,946	26,067	28.50	US$742,946
2025-03-06	2025-03-06	S Sale	2.3 Kuhlmann Shirley R. EVP and General Counsel Officer	26,067 -19.4% 28.50 US$742,946	26,067 -19.4%	28.50	US$742,946
2025-03-06	2025-03-05	S Sale	2.3 Kuhlmann Shirley R. EVP and General Counsel Officer	20,000 -13.0% 28.03 US$560,528	20,000 -13.0%	28.03	US$560,528
2025-03-05	2025-03-05	PrS Proposed sale	2.3 Kuhlmann Shirley R. Officer Officer	20,000 28.03 US$560,528	20,000	28.03	US$560,528
2025-03-06	2025-03-04	S Sale	2.3 Kuhlmann Shirley R. EVP and General Counsel Officer	40,000 -20.6% 28.08 US$1,123,160	40,000 -20.6%	28.08	US$1,123,160

Explore more

More insider trading research around Collegium Pharmaceutical Inc

More insider trades in United States

Similar Healthcare companies with insider activity

More Pharmaceuticals & Medical Research companies with insider activity

More Pharmaceuticals companies with insider activity

Insider trading in North America

Collegium Pharmaceutical Inc (COLL)

Track

Featured in screeners

Upgrade for signal details

Transactions

Insider

Sort by

Trades

Explore more